Osprey Medical inks new deal with GE Healthcare

Osprey Medical (ASX: OSP) will partner with US giant GE Healthcare to distribute its life saving medical devices across much of the globe.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Yesterday morning, Osprey Medical Inc (ASX: OSP) announced a strategic alliance with US giant GE Healthcare. The Osprey share price started trade yesterday strongly in response to the news before retreating to 4.4 cents per share at Thursday's close. 

What did Osprey announce?

Under the new agreement, GE Healthcare will exclusively distribute Osprey's products in Europe, Asia, Russia, Turkey, the Middle East, Africa and Central Asia.

The announcement reports that Osprey's DyeVert contrast minimisation devices will complement GE Healthcare's X-ray contrast media. Together, the technology will assist doctors in addressing the rising problem of acute kidney injury (AKI) following interventional coronary angiograms in patients with chronic kidney disease.

Osprey's technology is the only FDA-cleared medical device approved for reducing patient contrast exposure.

The 4-year agreement will see GE Healthcare commercialise Osprey's DyeVert portfolio. On average, the DyeVert technology reduces the amount of contrast that reaches the kidney by 40%, without reducing the image quality.

A word from management

In regard to the new alliance, Osprey CEO Mike McCormick said:

We are pleased to be partnering with GE Healthcare to be commercialising our products in global markets to address the rising problem of AKI following heart imaging procedures in patients with poor kidney function.

CEO of GE Healthcare's pharmaceutical diagnostics business Kevin O'Neill stated:

GE Healthcare and Osprey share a similar goal in improving patient outcomes. Both our product portfolios and educational efforts, which are aligned wit cardiology guidelines for AKI minimisation, offer interventional cardiologists the opportunity to safely image patients by reducing the risk of AKI.

Quarterly report highlights

On Tuesday, Osprey released its quarterly cash flow report for the period ending 30 June 2020.

The company reported a successful capital raising of $12.8 million from its entitlement offer and shortfall placement, and an additional $1.9 million from the US Government in the form of a pandemic recovery loan, a COVID-19 relief program for small US-based companies.

Additionally, Osprey reported a 7% fall in unit sales, due to COVID-19's impact on its worldwide heart procedures. However, as at 30 June, the company still maintained a cash balance of $14 million.

About the Osprey share price

After a strong initial start to the day on Thursday, rising more than 6%, Osprey's share price retreated.

The stock closed the day flat, trading for 4.4 cents, where it remains at the time of writing. Year-to-date, the Osprey share price is up 46.7%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A young man punches the air in delight as he reacts to great news on his mobile phone.
Broker Notes

These ASX 200 shares could rise 30% to 50%

Brokers have good things to say about these cheap shares.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Share Market News

Record CBA share price and Iran-Israel ceasefire lift ASX 200 financials to new peak

ASX financial shares led the 11 market sectors last week, gaining 1.82% and reaching a record high.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Broker Notes

10 Aussie stocks to buy in FY 2026

Let's see which shares analysts think could be buys in the upcoming financial year.

Read more »

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to the trading week for investors this Friday.

Read more »

A young boy points and smiles as he eats fried chicken.
Share Gainers

3 ASX All Ords shares smashing the benchmark this week

Investors are sending these three ASX All Ords shares rocketing 18% to more than 29% this week. But why?

Read more »

watch
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why APA, Flight Centre, Reece, and Transurban shares are falling today

These shares are having a tough finish to the week. But why?

Read more »